Complications of varicella zoster virus reactivation in HIV-infected homosexual men.
OBJECTIVE
To study the complication rate of varicella zoster virus (VZV) reactivation and the relationship between complications, presentation and localization of zoster and immune function in HIV disease.


METHODS
A total of 142 episodes of VZV reactivation in 113 out of 544 HIV-1-infected participants in the Amsterdam Cohort Study of homosexual men were studied. Persistent hyperkeratotic or necrotic skin lesions, post-herpetic neuralgia, other neurological events, ocular events and pneumonitis occurring within 6 months of the onset of the last episode of VZV reactivation were defined as complications, provided that other possible diagnoses were excluded and the event had been previously described in the literature as related to VZV reactivation.


RESULTS
Twenty-four complications occurred in 15 (11%) of these 142 episodes. Complications occurred exclusively in the 40 episodes with either multidermatomal or disseminated presentation, or a trigeminal localization, or both. In the group of episodes of unidermatomal zoster at a non-trigeminal localization no complications occurred. Twenty-one episodes of herpes zoster were localized in the trigeminal area. Localization was not significantly associated with the level of immune function. Compared to unidermatomal presentation (n = 120), multidermatomal (n = 15) and disseminated presentation (n = 7) occurred at lower median CD4+ cell counts (330, 240 and 50 x 10(6)/l, respectively; P = 0.003) and significantly lower levels of CD3 monoclonal antibodies or phytohaemagglutinin-induced T-cell reactivity in vitro. Complications were related to CD4+ cell counts, but in the cases of disseminated, multidermatomal or trigeminal zoster a CD4+ cell measurement provided no additional information on the risk of complications.


CONCLUSIONS
In HIV-infected individuals the extent of the clinical presentation and the occurrence of complications of VZV reactivation are related to the degree of immunodeficiency. In episodes of VZV reactivation with either multidermatomal or disseminated presentation or a trigeminal localization, or both the complication rate was high. CD4+ cell counts provided no additional information on the complication risk. Oral acyclovir appears to be sufficient as therapy for unidermatomal zoster at a non-trigeminal localization.
Veenstra
J
J
Department of Public Health and Environment, University of Amsterdam, The Netherlands.
van Praag
R M
RM
Krol
A
A
Wertheim van Dillen
P M
PM
Weigel
H M
HM
Schellekens
P T
PT
Lange
J M
JM
Coutinho
R A
RA
van der Meer
J T
JT
D000212:Acyclovir / Q000627:therapeutic use; D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use; D018791:CD4 Lymphocyte Count; D015331:Cohort Studies; D015658:HIV Infections / Q000150:complications* / Q000276:immunology; D015497:HIV-1; D006562:Herpes Zoster / Q000150:complications* / Q000188:drug therapy / Q000276:immunology; D014645:Herpesvirus 3, Human / Q000254:growth & development*; D018451:Homosexuality, Male; D006801:Humans; D008297:Male; D008875:Middle Aged; D017193:Skin Diseases, Viral / Q000150:complications / Q000188:drug therapy / Q000276:immunology; D014775:Virus Activation
D000998:Antiviral Agents; D000212:Acyclovir